chufangao/CTO huggingface dataset:
Clinical trial NCT03474458: A Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy
Official title: A Randomized Phase II/III Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: difficulty in recruitment
Enrollment: 19.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-11
Primary completion date: 2022-05-30
Completion date: 2022-05-30
Plan to share individual participant data: NO
Clinical trial NCT04830215: Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
Official title: A Phase 4, Multicenter, Open-label, Interventional Trial to Assess the Effects on Engagement of Flexible-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy for the Treatment of Adults With Major Depressive Disorder
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 122.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-04-01
Primary completion date: 2022-05-27
Completion date: 2022-05-27
Baseline population: The Enrolled Analysis Set included all participants who had signed the informed consent form (ICF) for the trial and had enrolled into the open-label treatment phase.
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03444103: A Pilot Trial of Clazakizumab in Late ABMR
Official title: Safety, Tolerability and Efficacy of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection After Kidney Transplantation - a Pilot Trial
Sponsor: Medical University of Vienna (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 20.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-01-16
Primary completion date: 2020-06-30
Completion date: 2020-06-30
Plan to share individual participant data: NO
Clinical trial NCT04447235: Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection
Official title: Randomized, Doubled-blind Phase II Trial Evaluating the Use of Ivermectin Plus Losartan for Prophylaxis of Severe Events in Cancer Patients With Recent Diagnosis of COVID-19
Acronym: TITAN
Sponsor: Instituto do Cancer do Estado de São Paulo (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: futility analysis has demonstrated no difference between arms
Enrollment: 77.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-23
Primary completion date: 2022-06-30
Completion date: 2022-06-30
Plan to share individual participant data: NO
IPD sharing description: no plan to share individual participant data
Clinical trial NCT04910152: Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD
Official title: A Single Arm, Open Label, Phase 1b/2 Study of Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD
Sponsor: Ohio State University Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-04-19
Primary completion date: 2023-09-28
Completion date: 2023-09-28
Plan to share individual participant data: NO
Clinical trial NCT03528876: FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal Adenocarcinoma
Official title: FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal Adenocarcinoma. The LOGIC Study
Acronym: LOGIC
Sponsor: University of Saskatchewan (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Combination of chemotherapy and Immunotherapy is a new Standard of care
Enrollment: 36.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-09-01
Primary completion date: 2020-10-29
Completion date: 2020-10-29
Plan to share individual participant data: NO
Clinical trial NCT05070312: Pharmacokinetics, Immunogenicity, Safety and Tolerability of MEDI3506 in Health Chinese Participants
Official title: A Phase I, Randomized, Double-blind, Placebo-controlled, Dose-ascending Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of MEDI3506 in Healthy Chinese Participants
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 39.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-08-23
Primary completion date: 2022-02-07
Completion date: 2022-02-07
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.~All request will be evaluated as per the AZ disclosure commitment:~https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessor) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT04837131: A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients
Official title: A Phase 2 Open-Label Pilot Study of the Safety and Tolerability of Ixazomib Administered Orally to Patients With Scleroderma-Related Interstitial Lung Disease
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low enrollment
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-04-28
Primary completion date: 2024-02-23
Completion date: 2024-02-23
Plan to share individual participant data: NO
Clinical trial NCT04474197: Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype
Official title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-864 in PiZZ Subjects
Sponsor: Vertex Pharmaceuticals Incorporated (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 44.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-07-24
Primary completion date: 2021-05-04
Completion date: 2021-05-04
Plan to share individual participant data: NO
IPD sharing description: Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Clinical trial NCT03998514: A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease
Official title: A Phase 1a/1b Study of Safety, Tolerability, and Pharmacokinetics of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease
Sponsor: CohBar, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 88.0 (ACTUAL)
Number of arms: 10.0
Start date: 2018-07-09
Primary completion date: 2021-04-19
Completion date: 2021-04-19
Plan to share individual participant data: NO
Clinical trial NCT04546425: 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
Official title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN AS A SERIES OF 2 INFANT DOSES AND 1 TODDLER DOSE IN HEALTHY INFANTS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1258.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-09
Primary completion date: 2022-04-22
Completion date: 2023-02-18
Baseline population: Safety analysis set included all participants who received at least 1 dose of 20vPnC or 13vPnC and had safety data assessed after any dose.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03071692: Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)
Official title: Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)
Acronym: PROMINENT
Sponsor: Kowa Research Institute, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The study was stopped for futility based on efficacy results at the interim analysis; no unexpected safety findings were observed.
Enrollment: 10544.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-03-23
Primary completion date: 2022-07-27
Completion date: 2022-07-27
Clinical trial NCT05331053: MicroRNA Activation of LOX-1 Mechanisms in Endometriosis
Official title: MicroRNA Activation of LOX-1 Mechanisms in Endometriosis
Sponsor: Penn State University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: SUSPENDED 
Why stopped: COVID halting human subjects research and preliminary data from this proposal were used to submit an NIH grant. The NIH grant was funded and 3 other protocols were launched.
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-05-01
Primary completion date: 2022-06-01
Completion date: 2024-08-31
Plan to share individual participant data: NO
Clinical trial NCT03812029: Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)
Official title: A Phase 2a, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis
Sponsor: Enyo Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 120.0 (ACTUAL)
Number of arms: 5.0
Start date: 2019-01-30
Primary completion date: 2021-06-16
Completion date: 2021-07-06
Baseline population: For Part A, data from the 3 vonafexor treatment groups were pooled and summarized. Due to the small number of subjects by treatment group in Part A, and as the Study EYP001 202 Part A PK results between groups were found to be nonlinear with similar exposure for the vonafexor 200 mg QD and vonafexor 400 mg QD groups, only the pooled vonafexor treatment group were compared with the placebo group.
Clinical trial NCT02420912: Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation
Official title: Nivolumab Combined With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 37.0 (ACTUAL)
Number of arms: 3.0
Start date: 2015-06-19
Primary completion date: 2022-02-14
Completion date: 2022-02-14
Clinical trial NCT04795596: Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers
Official title: Clinical Outcomes of Secondary Cytoreductive Surgery in Platinum-resistant Ovarian Cancers With Isolated Recurrence
Sponsor: Menoufia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: Poor accrual
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-01
Primary completion date: 2022-04-09
Completion date: 2022-04-09
Plan to share individual participant data: NO
Clinical trial NCT01998841: A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort
Official title: A Double-Blind, Placebo-Controlled Parallel-Group Study in Preclinical PSEN1 E280A Mutation Carriers Randomized to Crenezumab or Placebo, and in Non-Randomized, Placebo-Treated Non-Carriers From the Same Kindred, to Evaluate the Efficacy and Safety of Crenezumab in the Treatment of Autosomal-Dominant Alzheimer's Disease
Sponsor: Genentech, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 252.0 (ACTUAL)
Number of arms: 3.0
Start date: 2013-12-20
Primary completion date: 2022-03-22
Completion date: 2023-08-08
Baseline population: Intent-to-Treat (ITT) population included all randomized participants whether or not the participants received the assigned study treatment.
Clinical trial NCT00989651: Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Official title: A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 431.0 (ACTUAL)
Number of arms: 3.0
Start date: 2009-10-28
Primary completion date: 2016-09-02
Completion date: 2020-04-10
Clinical trial NCT04427072: Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
Official title: A Phase III, Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib Versus SoC Docetaxel Chemotherapy in Previously Treated Patients With EGFR wt, ALK Negative, Locally Advanced or Metastatic (Stage IIIB/IIIC or IV) NSCLC Harboring MET Exon 14 Skipping Mutation (METΔex14).
Acronym: GeoMETry-III
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 22.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-25
Primary completion date: 2023-02-15
Completion date: 2023-11-06
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT05013008: An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants
Official title: A Non-blinded Retrospective Biomarker add-on Study to FIGARO-DKD for Bioprofiling the Pharmacodynamic Response to Finerenone in FIGARO-DKD Subjects
Acronym: FIGARO-BM
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 951.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-08-18
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Baseline population: Modified biomarker full analysis set (mBFAS): All participants with valid informed consent for this biomarker study, which met the following criteria: a. Study enrollment criteria as defined in the study protocol. b. Analyzed biomarker samples at Visit 3 (4 months) and Visit 11 (36 months); Biomarker samples that were shipped at ambient temperatures were not analyzed. c. On Treatment at Visit 3 and Visit 11.
Limitations and caveats: This study was a retrospective, add-on study to the multi-center, interventional Phase 3 study FIGARO-DKD (NCT02545049). Blood plasma samples that were originally collected for PK analysis during the conduct of FIGARO-DKD study. Visit 3 (4 months of treatment) data were considered as baseline for the biomarker measurements as no pre-dose samples were available from FIGARO-DKD.
Plan to share individual participant data: NO
IPD sharing description: Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA Principles for responsible clinical trial data sharing. This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.~Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Clinical trial NCT02236572: Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score
Official title: A Neoadjuvant Phase II Trial of Aromatase Inhibitors in Combination With Everolimus in Postmenopausal Women With Hormone Receptor Positive/HER2 Negative Breast Cancers With Low and Intermediate Risk (< 25) Oncotype Dx Recurrence Scores
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Phase 2 of recruitment was contingent on 5 of 15 patients responding, which did not occur.
Enrollment: 17.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-11-29
Primary completion date: 2021-03-01
Completion date: 2021-03-01
Clinical trial NCT03335436: Gabapentin in the Post-cesarean Pain Management of Buprenorphine Patient
Official title: A Randomized, Double-blind, Placebo-controlled Trial of Gabapentin in the Post-cesarean Pain Management of Buprenorphine Patient
Sponsor: Vanderbilt University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Lack of enrollment
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-04-01
Primary completion date: 2020-11-30
Completion date: 2020-12-31
Plan to share individual participant data: NO
Clinical trial NCT05446168: Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Tributyrin Supplementation
Official title: Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Tributyrin Supplementation
Acronym: BUTTER
Sponsor: University of Michigan (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Withdrawal of funding
Enrollment: 18.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-07-01
Primary completion date: 2023-09-26
Completion date: 2023-09-26
Plan to share individual participant data: NO
Clinical trial NCT04529954: Anti-Epilepsy Medication Valproate Administered Via ICV Route and Catheters and Pumps for CSF Infusion
Official title: An Open-Label Extension Study to Investigate the Long-Term Safety, and Tolerability of Intracerebroventricular (ICV) Delivery of Valproate in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary Generalization
Sponsor: Cerebral Therapeutics LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Company Decision
Enrollment: 20.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-01-01
Primary completion date: 2024-03-01
Completion date: 2024-03-01
Plan to share individual participant data: NO
Clinical trial NCT03907969: A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.
Official title: A Phase I/IIa, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD7648 Monotherapy or in Combination With Either Cytotoxic Chemotherapies or Novel Anti-Cancer Agents in Patients With Advanced Malignancies
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 30.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-09
Primary completion date: 2022-12-07
Completion date: 2022-12-07
Baseline population: All patients who received at least 1 dose of any study treatment.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment:~https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.~Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT04139395: 68Ga Citrate PET/MRI for Evaluation of Fever of Unknown Origin (FUO)
Official title: 68Ga Citrate PET/MRI for Evaluation of Fever of Unknown Origin (FUO)
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Not feasible at this time.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-01-15
Primary completion date: 2020-12-20
Completion date: 2021-12-20
Plan to share individual participant data: NO